Oncology Central

Are we entering the era of combination therapy for melanoma?


Unprecedented responses to newly available treatments for metastatic melanoma have dramatically changed the therapeutic landscape of this disease during the last decade, highlighted by eight new US FDA approved therapies since 2011. Two approaches include modulation of the immune system with checkpoint inhibitors and targeting oncogenic drivers of melanoma using BRAF and MEK inhibitors (BRAFi and MEKi). As these therapies show more promise, the number of clinical trials exploring various combinations continues to increase.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.